UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM N-CSRS
Investment Company Act file number: 811-00043
Deutsche DWS Investment Trust
(Exact Name of Registrant as Specified in Charter)
875 Third Avenue
New York, NY 10022-6225
(Address of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, including Area Code: (212) 454-4500
Diane Kenneally
100 Summer Street
Boston, MA 02110
(Name and Address of Agent for Service)
Date of fiscal year end: | 9/30 |
Date of reporting period: | 3/31/2022 |
ITEM 1. | REPORT TO STOCKHOLDERS |
(a) | |
2 | | | DWS CROCI® U.S. Fund |
DWS CROCI® U.S. Fund | | | 3 |
Performance Summary | March 31, 2022 (Unaudited) |
Class A | 6-Month ‡ | 1-Year | 5-Year | Life
of Fund* |
Average Annual Total Returns as of 3/31/22 | ||||
Unadjusted for Sales Charge | 4.31% | 8.00% | 6.67% | 5.52% |
Adjusted
for the Maximum Sales Charge (max 5.75% load) |
–1.68% | 1.79% | 5.41% | 4.62% |
Russell 1000® Value Index† | 6.98% | 11.67% | 10.29% | 9.53% |
Class T | 6-Month ‡ | 1-Year | 5-Year | Life
of Fund* |
Average Annual Total Returns as of 3/31/22 | ||||
Unadjusted for Sales Charge | 4.44% | 8.03% | 6.71% | 5.52% |
Adjusted
for the Maximum Sales Charge (max 2.50% load) |
1.83% | 5.33% | 6.17% | 5.13% |
Russell 1000® Value Index† | 6.98% | 11.67% | 10.29% | 10.55% |
Class C | 6-Month ‡ | 1-Year | 5-Year | Life
of Fund* |
Average Annual Total Returns as of 3/31/22 | ||||
Unadjusted for Sales Charge | 3.98% | 7.05% | 5.85% | 4.70% |
Adjusted
for the Maximum Sales Charge (max 1.00% CDSC) |
2.98% | 7.05% | 5.85% | 4.70% |
Russell 1000® Value Index† | 6.98% | 11.67% | 10.29% | 9.53% |
Class R | 6-Month ‡ | 1-Year | 5-Year | Life
of Fund* |
Average Annual Total Returns as of 3/31/22 | ||||
No Sales Charges | 4.17% | 7.67% | 6.35% | 5.15% |
Russell 1000® Value Index† | 6.98% | 11.67% | 10.29% | 10.22% |
Class R6 | 6-Month ‡ | 1-Year | 5-Year | Life
of Fund* |
Average Annual Total Returns as of 3/31/22 | ||||
No Sales Charges | 4.59% | 8.37% | 7.08% | 5.89% |
Russell 1000® Value Index† | 6.98% | 11.67% | 10.29% | 9.53% |
4 | | | DWS CROCI® U.S. Fund |
Class S | 6-Month ‡ | 1-Year | 5-Year | Life
of Fund* |
Average Annual Total Returns as of 3/31/22 | ||||
No Sales Charges | 4.55% | 8.33% | 7.01% | 5.82% |
Russell 1000® Value Index† | 6.98% | 11.67% | 10.29% | 9.53% |
Institutional Class | 6-Month ‡ | 1-Year | 5-Year | Life
of Fund* |
Average Annual Total Returns as of 3/31/22 | ||||
No Sales Charges | 4.55% | 8.33% | 6.99% | 5.83% |
Russell 1000® Value Index† | 6.98% | 11.67% | 10.29% | 9.53% |
DWS CROCI® U.S. Fund | | | 5 |
* | The Fund commenced operations on April 13, 2015. Class T shares commenced operations on June 5, 2017. Class R shares commenced operations on December 9, 2016. |
† | Russell 1000® Value Index is an unmanaged market capitalization-weighted index of value-oriented stocks of the largest U.S. domiciled companies that are included in the Russell 1000 Index. Value-oriented stocks tend to have lower price-to-book ratios and lower forecasted growth values. Russell 1000 Index is an unmanaged price-only index of the 1,000 largest capitalized companies that are domiciled in the U.S. and whose common stocks are traded. |
‡ | Total returns shown for periods less than one year are not annualized. |
Class A | Class T | Class C | Class R | Class R6 | Class S | Institutional
Class | |
Net Asset Value | |||||||
3/31/22 | $12.37 | $12.38 | $12.25 | $12.37 | $12.38 | $12.38 | $12.37 |
9/30/21 | $12.02 | $12.02 | $11.84 | $12.00 | $12.04 | $12.04 | $12.03 |
Distribution Information as of 3/31/22 | |||||||
Income Dividends, Six Months | $ .18 | $ .18 | $ .06 | $ .14 | $ .22 | $ .22 | $ .22 |
6 | | | DWS CROCI® U.S. Fund |
DWS CROCI® U.S. Fund | | | 7 |
Portfolio Summary | (Unaudited) |
Asset Allocation (As a % of Investment Portfolio excluding Securities Lending Collateral) | 3/31/22 | 9/30/21 |
Common Stocks | 99% | 100% |
Cash Equivalents | 1% | 0% |
100% | 100% |
Sector Diversification (As a % of Investment Portfolio excluding Securities Lending Collateral and Cash Equivalents) | 3/31/22 | 9/30/21 |
Information Technology | 27% | 32% |
Health Care | 24% | 21% |
Financials | 13% | 11% |
Communication Services | 10% | 7% |
Consumer Discretionary | 9% | 10% |
Consumer Staples | 5% | 10% |
Materials | 5% | 1% |
Industrials | 5% | 7% |
Energy | 2% | 1% |
100% | 100% |
8 | | | DWS CROCI® U.S. Fund |
Ten Largest Equity Holdings at March 31, 2022 (35.4% of Net Assets) | |
1 Bristol-Myers Squibb Co. | 4.9% |
Producer of diversified pharmaceuticals and other products | |
2 Johnson & Johnson | 4.6% |
Provider of health care products | |
3 Meta Platforms, Inc. | 4.4% |
Operator of social networking Web site | |
4 Alphabet, Inc. | 3.9% |
Holding company with subsidiaries that provide Web-based search, maps, hardware products and various software applications | |
5 Apple, Inc. | 3.4% |
Designs, manufactures and markets personal computers and related computing and mobile-communication devices | |
6 AbbVie, Inc. | 3.0% |
Developer of pharmaceutical products | |
7 Regeneron Pharmaceuticals, Inc. | 3.0% |
Operator of a drug research and development company | |
8 Pfizer, Inc. | 2.9% |
Manufacturer of prescription pharmaceuticals and nonprescription self-medications | |
9 SS&C Technologies Holdings, Inc. | 2.8% |
Developer of financial software solutions | |
10 Expeditors International of Washington, Inc. | 2.5% |
Provider of international logistics services |
DWS CROCI® U.S. Fund | | | 9 |
Investment Portfolio | as of March 31, 2022 (Unaudited) |
Shares | Value ($) | ||
Common Stocks 99.3% | |||
Communication Services 9.7% | |||
Interactive Media & Services 8.3% | |||
Alphabet, Inc. “A” * | 9,842 | 27,374,047 | |
Meta Platforms, Inc. “A” * | 137,953 | 30,675,229 | |
58,049,276 | |||
Media 1.4% | |||
Fox Corp. “A” | 248,488 | 9,802,851 | |
Consumer Discretionary 9.3% | |||
Hotels, Restaurants & Leisure 0.6% | |||
Boyd Gaming Corp. | 62,480 | 4,109,934 | |
Household Durables 2.7% | |||
D.R. Horton, Inc. | 227,018 | 16,915,111 | |
Garmin Ltd. | 16,051 | 1,903,809 | |
18,818,920 | |||
Internet & Direct Marketing Retail 1.1% | |||
eBay, Inc. | 126,549 | 7,246,196 | |
Multiline Retail 2.4% | |||
Dollar General Corp. | 76,697 | 17,075,053 | |
Specialty Retail 2.3% | |||
AutoNation, Inc.* | 48,021 | 4,781,931 | |
Bath & Body Works, Inc. | 32,636 | 1,560,001 | |
Lowe’s Companies, Inc. | 41,658 | 8,422,831 | |
Signet Jewelers Ltd. | 22,128 | 1,608,706 | |
16,373,469 | |||
Textiles, Apparel & Luxury Goods 0.2% | |||
Tapestry, Inc. | 43,368 | 1,611,121 | |
Consumer Staples 5.3% | |||
Food & Staples Retailing 1.9% | |||
Kroger Co. | 228,809 | 13,126,772 | |
Food Products 2.0% | |||
J M Smucker Co. | 51,509 | 6,974,834 | |
Tyson Foods, Inc. “A” | 77,587 | 6,954,123 | |
13,928,957 | |||
Tobacco 1.4% | |||
Altria Group, Inc. | 189,891 | 9,921,805 |
10 | | | DWS CROCI® U.S. Fund |
Shares | Value ($) | ||
Energy 1.6% | |||
Oil, Gas & Consumable Fuels | |||
ConocoPhillips | 34,997 | 3,499,700 | |
ONEOK, Inc. (a) | 36,019 | 2,544,022 | |
Pioneer Natural Resources Co. | 21,879 | 5,470,406 | |
11,514,128 | |||
Financials 12.3% | |||
Banks 5.7% | |||
Bank of America Corp. | 200,384 | 8,259,829 | |
Citigroup, Inc. | 203,616 | 10,873,094 | |
JPMorgan Chase & Co. | 77,414 | 10,553,077 | |
U.S. Bancorp. | 198,787 | 10,565,529 | |
40,251,529 | |||
Capital Markets 1.8% | |||
Bank of New York Mellon Corp. | 90,472 | 4,490,125 | |
State Street Corp. | 90,483 | 7,882,879 | |
12,373,004 | |||
Consumer Finance 4.8% | |||
Capital One Financial Corp. | 135,569 | 17,798,854 | |
Discover Financial Services | 64,450 | 7,101,746 | |
Synchrony Financial | 261,008 | 9,085,688 | |
33,986,288 | |||
Health Care 24.2% | |||
Biotechnology 7.3% | |||
AbbVie, Inc. | 128,444 | 20,822,057 | |
Gilead Sciences, Inc. | 99,064 | 5,889,355 | |
Regeneron Pharmaceuticals, Inc.* | 29,660 | 20,715,137 | |
Vertex Pharmaceuticals, Inc.* | 14,342 | 3,742,832 | |
51,169,381 | |||
Health Care Providers & Services 4.1% | |||
HCA Healthcare, Inc. | 29,220 | 7,323,116 | |
Laboratory Corp. of America Holdings* | 40,368 | 10,643,427 | |
Quest Diagnostics, Inc. | 63,197 | 8,649,141 | |
Tenet Healthcare Corp.* | 24,860 | 2,136,966 | |
28,752,650 | |||
Pharmaceuticals 12.8% | |||
Bristol-Myers Squibb Co. | 470,447 | 34,356,744 | |
Johnson & Johnson | 183,565 | 32,533,225 |
DWS CROCI® U.S. Fund | | | 11 |
Shares | Value ($) | ||
Merck & Co., Inc. | 30,098 | 2,469,541 | |
Pfizer, Inc. | 399,449 | 20,679,475 | |
90,038,985 | |||
Industrials 4.9% | |||
Air Freight & Logistics 2.8% | |||
C.H. Robinson Worldwide, Inc. | 19,454 | 2,095,390 | |
Expeditors International of Washington, Inc. | 173,117 | 17,858,750 | |
19,954,140 | |||
Industrial Conglomerates 1.3% | |||
3M Co. | 62,851 | 9,357,257 | |
Machinery 0.5% | |||
Stanley Black & Decker, Inc. | 22,473 | 3,141,501 | |
Professional Services 0.3% | |||
ManpowerGroup, Inc. | 19,756 | 1,855,483 | |
Information Technology 26.8% | |||
Communications Equipment 1.7% | |||
Cisco Systems, Inc. | 213,101 | 11,882,512 | |
Electronic Equipment, Instruments & Components 1.1% | |||
Flex Ltd.* | 105,222 | 1,951,868 | |
Jabil, Inc. | 91,939 | 5,675,394 | |
7,627,262 | |||
IT Services 5.8% | |||
Amdocs Ltd. | 205,430 | 16,888,400 | |
Cognizant Technology Solutions Corp. “A” | 172,508 | 15,468,793 | |
International Business Machines Corp. | 65,260 | 8,485,105 | |
40,842,298 | |||
Semiconductors & Semiconductor Equipment 8.0% | |||
Applied Materials, Inc. | 83,216 | 10,967,869 | |
Broadcom, Inc. | 24,925 | 15,694,774 | |
KLA Corp. | 15,737 | 5,760,686 | |
Lam Research Corp. | 9,446 | 5,078,264 | |
Micron Technology, Inc. | 86,891 | 6,767,940 | |
QUALCOMM, Inc. | 60,982 | 9,319,269 | |
Teradyne, Inc. (a) | 22,025 | 2,604,016 | |
56,192,818 | |||
Software 6.1% | |||
Microsoft Corp. | 36,980 | 11,401,304 |
12 | | | DWS CROCI® U.S. Fund |
Shares | Value ($) | ||
Oracle Corp. | 145,685 | 12,052,520 | |
SS&C Technologies Holdings, Inc. | 257,716 | 19,333,854 | |
42,787,678 | |||
Technology Hardware, Storage & Peripherals 4.1% | |||
Apple, Inc. | 138,067 | 24,107,879 | |
Hewlett Packard Enterprise Co. | 124,479 | 2,080,044 | |
HP, Inc. | 77,479 | 2,812,488 | |
29,000,411 | |||
Materials 5.2% | |||
Chemicals 3.3% | |||
LyondellBasell Industries NV “A” | 167,652 | 17,237,979 | |
Olin Corp. | 121,301 | 6,341,616 | |
23,579,595 | |||
Containers & Packaging 0.3% | |||
Westrock Co. | 41,306 | 1,942,621 | |
Metals & Mining 1.6% | |||
Nucor Corp. | 75,737 | 11,258,305 | |
Total Common Stocks (Cost $649,709,840) | 697,572,200 | ||
Securities Lending Collateral 0.5% | |||
DWS
Government & Agency Securities Portfolio “DWS Government Cash Institutional Shares” , 0.23% (b) (c) (Cost $3,739,124) |
3,739,124 | 3,739,124 | |
Cash Equivalents 0.7% | |||
DWS
Central Cash Management Government Fund, 0.28% (b) (Cost $4,615,364) |
4,615,364 | 4,615,364 |
%
of Net Assets |
Value ($) | ||
Total Investment Portfolio (Cost $658,064,328) | 100.5 | 705,926,688 | |
Other Assets and Liabilities, Net | (0.5) | (3,659,208) | |
Net Assets | 100.0 | 702,267,480 |
DWS CROCI® U.S. Fund | | | 13 |
Value
($) at 9/30/2021 |
Pur-
chases Cost ($) |
Sales
Proceeds ($) |
Net
Real- ized Gain/ (Loss) ($) |
Net
Change in Unreal- ized Appreci- ation (Depreci- ation) ($) |
Income
($) |
Capital
Gain Distri- butions ($) |
Number
of Shares at 3/31/2022 |
Value
($) at 3/31/2022 |
Securities Lending Collateral 0.5% | ||||||||
DWS Government & Agency Securities Portfolio “DWS Government Cash Institutional Shares” , 0.23% (b) (c) | ||||||||
11,815,247 | — | 8,076,123 (d) | — | — | 1,553 | — | 3,739,124 | 3,739,124 |
Cash Equivalents 0.7% | ||||||||
DWS Central Cash Management Government Fund, 0.28% (b) | ||||||||
1,533,116 | 27,724,520 | 24,642,272 | — | — | 1,388 | — | 4,615,364 | 4,615,364 |
13,348,363 | 27,724,520 | 32,718,395 | — | — | 2,941 | — | 8,354,488 | 8,354,488 |
* | Non-income producing security. |
(a) | All or a portion of these securities were on loan. In addition, “Other Assets and Liabilities, Net” may include pending sales that are also on loan. The value of securities loaned at March 31, 2022 amounted to $3,580,360, which is 0.5% of net assets. |
(b) | Affiliated fund managed by DWS Investment Management Americas, Inc. The rate shown is the annualized seven-day yield at period end. |
(c) | Represents cash collateral held in connection with securities lending. Income earned by the Fund is net of borrower rebates. |
(d) | Represents the net increase (purchase cost) or decrease (sales proceeds) in the amount invested in cash collateral for the period ended March 31, 2022. |
14 | | | DWS CROCI® U.S. Fund |
Assets | Level 1 | Level 2 | Level 3 | Total |
Common Stocks (a) | $697,572,200 | $— | $— | $697,572,200 |
Short-Term Investments (a) | 8,354,488 | — | — | 8,354,488 |
Total | $705,926,688 | $ — | $ — | $705,926,688 |
(a) | See Investment Portfolio for additional detailed categorizations. |
DWS CROCI® U.S. Fund | | | 15 |
Assets | |
Investments in non-affiliated securities, at value (cost $649,709,840) — including $3,580,360 of securities loaned | $ 697,572,200 |
Investment in DWS Government & Agency Securities Portfolio (cost $3,739,124)* | 3,739,124 |
Investment in DWS Central Cash Management Government Fund (cost $4,615,364) | 4,615,364 |
Cash | 384 |
Receivable for Fund shares sold | 5,020 |
Dividends receivable | 786,788 |
Interest receivable | 912 |
Other assets | 76,897 |
Total assets | 706,796,689 |
Liabilities | |
Payable upon return of securities loaned | 3,739,124 |
Payable for Fund shares redeemed | 220,592 |
Accrued management fee | 251,324 |
Accrued Trustees' fees | 3,131 |
Other accrued expenses and payables | 315,038 |
Total liabilities | 4,529,209 |
Net assets, at value | $ 702,267,480 |
Net Assets Consist of | |
Distributable earnings (loss) | 71,269,179 |
Paid-in capital | 630,998,301 |
Net assets, at value | $ 702,267,480 |
* | Represents collateral on securities loaned. |
16 | | | DWS CROCI® U.S. Fund |
Net Asset Value | |
Class A | |
Net
Asset Value and redemption price per share ($102,263,165 ÷ 8,264,271 outstanding shares of beneficial interest, $.01 par value, unlimited number of shares authorized) |
$ 12.37 |
Maximum offering price per share (100 ÷ 94.25 of $12.37) | $ 13.12 |
Class T | |
Net
Asset Value and redemption price per share ($13,486 ÷ 1,089 outstanding shares of beneficial interest, $.01 par value, unlimited number of shares authorized) |
$ 12.38 |
Maximum offering price per share (100 ÷ 97.50 of $12.38) | $ 12.70 |
Class C | |
Net
Asset Value, offering and redemption price (subject to contingent deferred sales charge) per share ($1,531,178 ÷ 124,951 outstanding shares of beneficial interest, $.01 par value, unlimited number of shares authorized) |
$ 12.25 |
Class R | |
Net
Asset Value, offering and redemption price per share ($1,320,454 ÷ 106,706 outstanding shares of beneficial interest, $.01 par value, unlimited number of shares authorized) |
$ 12.37 |
Class R6 | |
Net
Asset Value, offering and redemption price per share ($262,380 ÷ 21,195 outstanding shares of beneficial interest, $.01 par value, unlimited number of shares authorized) |
$ 12.38 |
Class S | |
Net
Asset Value, offering and redemption price per share ($590,735,140 ÷ 47,723,970 outstanding shares of beneficial interest, $.01 par value, unlimited number of shares authorized) |
$ 12.38 |
Institutional Class | |
Net
Asset Value, offering and redemption price per share ($6,141,677 ÷ 496,512 outstanding shares of beneficial interest, $.01 par value, unlimited number of shares authorized) |
$ 12.37 |
DWS CROCI® U.S. Fund | | | 17 |
Investment Income | |
Income: | |
Dividends | $ 7,120,855 |
Income distributions — DWS Central Cash Management Government Fund | 1,388 |
Securities lending income, net of borrower rebates | 1,553 |
Total income | 7,123,796 |
Expenses: | |
Management fee | 1,523,880 |
Administration fee | 347,803 |
Services to shareholders | 405,115 |
Distribution and service fees | 138,682 |
Custodian fee | 4,294 |
Professional fees | 43,680 |
Reports to shareholders | 25,421 |
Registration fees | 34,348 |
Trustees' fees and expenses | 13,252 |
Other | 21,353 |
Total expenses before expense reductions | 2,557,828 |
Expense reductions | (3,103) |
Total expenses after expense reductions | 2,554,725 |
Net investment income | 4,569,071 |
Realized and Unrealized Gain (Loss) | |
Net realized gain (loss) from investments | 23,416,275 |
Change in net unrealized appreciation (depreciation) on investments | 3,925,969 |
Net gain (loss) | 27,342,244 |
Net increase (decrease) in net assets resulting from operations | $ 31,911,315 |
18 | | | DWS CROCI® U.S. Fund |
Six
Months Ended March 31, 2022 |
Year
Ended September 30, | |
Increase (Decrease) in Net Assets | (Unaudited) | 2021 |
Operations: | ||
Net investment income | $ 4,569,071 | $ 12,831,399 |
Net realized gain (loss) | 23,416,275 | 82,997,431 |
Change
in net unrealized appreciation (depreciation) |
3,925,969 | 57,437,122 |
Net increase (decrease) in net assets resulting from operations | 31,911,315 | 153,265,952 |
Distributions to shareholders: | ||
Class A | (1,478,833) | (2,109,892) |
Class T | (195) | (242) |
Class C | (8,012) | (26,033) |
Class R | (15,378) | (21,927) |
Class R6 | (4,600) | (3,390) |
Class S | (10,364,608) | (13,329,219) |
Institutional Class | (113,636) | (161,563) |
Total distributions | (11,985,262) | (15,652,266) |
Fund share transactions: | ||
Proceeds from shares sold | 5,761,794 | 23,794,341 |
Reinvestment of distributions | 11,436,771 | 14,877,731 |
Payments for shares redeemed | (33,642,635) | (117,429,156) |
Net increase (decrease) in net assets from Fund share transactions | (16,444,070) | (78,757,084) |
Increase (decrease) in net assets | 3,481,983 | 58,856,602 |
Net assets at beginning of period | 698,785,497 | 639,928,895 |
Net assets at end of period | $702,267,480 | $ 698,785,497 |
DWS CROCI® U.S. Fund | | | 19 |
DWS CROCI® U.S. Fund — Class A | ||||||
Six
Months Ended 3/31/22 |
Years Ended September 30, | |||||
(Unaudited) | 2021 | 2020 | 2019 | 2018 | 2017 | |
Selected Per Share Data | ||||||
Net asset value, beginning of period | $12.02 | $9.80 | $11.70 | $11.83 | $11.21 | $9.51 |
Income (loss) from investment operations: | ||||||
Net investment incomea | .06 | .18 | .21 | .21 | .17 | .16 |
Net realized and unrealized gain (loss) | .47 | 2.26 | (1.41) | .04 | .69 | 1.55 |
Total from investment operations | .53 | 2.44 | (1.20) | .25 | .86 | 1.71 |
Less distributions from: | ||||||
Net investment income | (.18) | (.22) | (.19) | (.25) | (.11) | (.01) |
Net realized gains | — | — | (.51) | (.13) | (.13) | — |
Total distributions | (.18) | (.22) | (.70) | (.38) | (.24) | (.01) |
Net asset value, end of period | $12.37 | $12.02 | $9.80 | $11.70 | $11.83 | $11.21 |
Total Return (%)b | 4.31 * | 25.24 | (11.40) | 2.61 | 7.87 | 17.94 |
Ratios to Average Net Assets and Supplemental Data | ||||||
Net assets, end of period ($ millions) | 102 | 103 | 101 | 132 | 147 | 154 |
Ratio of expenses (%) | .99 ** | .98 | 1.01 | .99 | 1.01 | .96 |
Ratio of net investment income (%) | .99 ** | 1.59 | 1.94 | 1.88 | 1.48 | 1.50 |
Portfolio turnover rate (%) | 30 * | 108 | 138 | 95 | 98 | 100 |
a | Based on average shares outstanding during the period. |
b | Total return does not reflect the effect of any sales charges. |
* | Not annualized |
** | Annualized |
20 | | | DWS CROCI® U.S. Fund |
DWS CROCI® U.S. Fund — Class T | ||||||
Six
Months Ended 3/31/22 |
Years Ended September 30, | Period
Ended | ||||
(Unaudited) | 2021 | 2020 | 2019 | 2018 | 9/30/17 a | |
Selected Per Share Data | ||||||
Net asset value, beginning of period | $12.02 | $9.81 | $11.71 | $11.85 | $11.21 | $10.68 |
Income (loss) from investment operations: | ||||||
Net investment incomeb | .07 | .19 | .21 | .22 | .18 | .05 |
Net realized and unrealized gain (loss) | .47 | 2.25 | (1.40) | .03 | .69 | .48 |
Total from investment operations | .54 | 2.44 | (1.19) | .25 | .87 | .53 |
Less distributions from: | ||||||
Net investment income | (.18) | (.23) | (.20) | (.26) | (.10) | — |
Net realized gains | — | — | (.51) | (.13) | (.13) | — |
Total distributions | (.18) | (.23) | (.71) | (.39) | (.23) | — |
Net asset value, end of period | $12.38 | $12.02 | $9.81 | $11.71 | $11.85 | $11.21 |
Total Return (%)c | 4.44 * | 25.23 | (11.32) | 2.70 | 7.87 | 4.96 d* |
Ratios to Average Net Assets and Supplemental Data | ||||||
Net assets, end of period ($ thousands) | 13 | 13 | 10 | 12 | 11 | 10 |
Ratio
of expenses before expense reductions (%) |
.92 ** | .94 | .92 | .92 | .93 | 1.05 ** |
Ratio
of expenses after expense reductions (%) |
.92 ** | .94 | .92 | .92 | .93 | 1.04 ** |
Ratio of net investment income (%) | 1.08 ** | 1.63 | 2.04 | 1.97 | 1.57 | 1.53 ** |
Portfolio turnover rate (%) | 30 * | 108 | 138 | 95 | 98 | 100 e |
a | For the period from June 5, 2017 (commencement of operations) to September 30, 2017. |
b | Based on average shares outstanding during the period. |
c | Total return does not reflect the effect of any sales charges. |
d | Total return would have been lower had certain expenses not been reduced. |
e | Represents the Fund’s portfolio turnover rate for the year ended September 30, 2017. |
* | Not annualized |
** | Annualized |
DWS CROCI® U.S. Fund | | | 21 |
DWS CROCI® U.S. Fund — Class C | ||||||
Six
Months Ended 3/31/22 |
Years Ended September 30, | |||||
(Unaudited) | 2021 | 2020 | 2019 | 2018 | 2017 | |
Selected Per Share Data | ||||||
Net asset value, beginning of period | $11.84 | $9.66 | $11.55 | $11.68 | $11.06 | $9.45 |
Income (loss) from investment operations: | ||||||
Net investment incomea | .01 | .09 | .12 | .12 | .08 | .08 |
Net realized and unrealized gain (loss) | .46 | 2.23 | (1.40) | .05 | .69 | 1.53 |
Total from investment operations | .47 | 2.32 | (1.28) | .17 | .77 | 1.61 |
Less distributions from: | ||||||
Net investment income | (.06) | (.14) | (.10) | (.17) | (.02) | — |
Net realized gains | — | — | (.51) | (.13) | (.13) | — |
Total distributions | (.06) | (.14) | (.61) | (.30) | (.15) | — |
Net asset value, end of period | $12.25 | $11.84 | $9.66 | $11.55 | $11.68 | $11.06 |
Total Return (%)b | 3.98 c* | 24.18 | (12.16) c | 1.90 | 7.05 | 17.04 |
Ratios to Average Net Assets and Supplemental Data | ||||||
Net assets, end of period ($ millions) | 2 | 2 | 2 | 4 | 6 | 16 |
Ratio
of expenses before expense reductions (%) |
1.86 ** | 1.84 | 1.81 | 1.73 | 1.75 | 1.72 |
Ratio
of expenses after expense reductions (%) |
1.76 ** | 1.84 | 1.78 | 1.73 | 1.75 | 1.72 |
Ratio of net investment income (%) | .23 ** | .78 | 1.15 | 1.11 | .70 | .74 |
Portfolio turnover rate (%) | 30 * | 108 | 138 | 95 | 98 | 100 |
a | Based on average shares outstanding during the period. |
b | Total return does not reflect the effect of any sales charges. |
c | Total return would have been lower had certain expenses not been reduced. |
* | Not annualized |
** | Annualized |
22 | | | DWS CROCI® U.S. Fund |
DWS CROCI® U.S. Fund — Class R | ||||||
Six
Months Ended 3/31/22 |
Years Ended September 30, | Period
Ended | ||||
(Unaudited) | 2021 | 2020 | 2019 | 2018 | 9/30/17 a | |
Selected Per Share Data | ||||||
Net asset value, beginning of period | $12.00 | $9.78 | $11.68 | $11.82 | $11.19 | $9.67 |
Income (loss) from investment operations: | ||||||
Net investment incomeb | .05 | .15 | .18 | .17 | .14 | .10 |
Net realized and unrealized gain (loss) | .46 | 2.26 | (1.41) | .04 | .70 | 1.42 |
Total from investment operations | .51 | 2.41 | (1.23) | .21 | .84 | 1.52 |
Less distributions from: | ||||||
Net investment income | (.14) | (.19) | (.16) | (.22) | (.08) | — |
Net realized gains | — | — | (.51) | (.13) | (.13) | — |
Total distributions | (.14) | (.19) | (.67) | (.35) | (.21) | — |
Net asset value, end of period | $12.37 | $12.00 | $9.78 | $11.68 | $11.82 | $11.19 |
Total Return (%) | 4.17 c* | 24.92 c | (11.70) c | 2.30 c | 7.54 c | 15.72 * |
Ratios to Average Net Assets and Supplemental Data | ||||||
Net assets, end of period ($ millions) | 1 | 1 | 1 | 2 | 2 | 2 |
Ratio
of expenses before expense reductions (%) |
1.32 ** | 1.29 | 1.33 | 1.34 | 1.39 | 1.27 ** |
Ratio
of expenses after expense reductions (%) |
1.26 ** | 1.28 | 1.30 | 1.29 | 1.29 | 1.27 ** |
Ratio of net investment income (%) | .72 ** | 1.28 | 1.66 | 1.57 | 1.20 | 1.19 ** |
Portfolio turnover rate (%) | 30 * | 108 | 138 | 95 | 98 | 100 d |
a | For the period from December 9, 2016 (commencement of operations) to September 30, 2017. |
b | Based on average shares outstanding during the period. |
c | Total return would have been lower had certain expenses not been reduced. |
d | Represents the Fund’s portfolio turnover rate for the year ended September 30, 2017. |
* | Not annualized |
** | Annualized |
DWS CROCI® U.S. Fund | | | 23 |
DWS CROCI® U.S. Fund — Class R6 | ||||||
Six
Months Ended 3/31/22 |
Years Ended September 30, | |||||
(Unaudited) | 2021 | 2020 | 2019 | 2018 | 2017 | |
Selected Per Share Data | ||||||
Net asset value, beginning of period | $12.04 | $9.82 | $11.73 | $11.87 | $11.24 | $9.53 |
Income (loss) from investment operations: | ||||||
Net investment incomea | .09 | .22 | .25 | .26 | .22 | .20 |
Net realized and unrealized gain (loss) | .47 | 2.26 | (1.40) | .02 | .70 | 1.54 |
Total from investment operations | .56 | 2.48 | (1.15) | .28 | .92 | 1.74 |
Less distributions from: | ||||||
Net investment income | (.22) | (.26) | (.25) | (.29) | (.16) | (.03) |
Net realized gains | — | — | (.51) | (.13) | (.13) | — |
Total distributions | (.22) | (.26) | (.76) | (.42) | (.29) | (.03) |
Net asset value, end of period | $12.38 | $12.04 | $9.82 | $11.73 | $11.87 | $11.24 |
Total Return (%) | 4.59 * | 25.68 | (11.08) b | 3.07 b | 8.23 b | 18.30 b |
Ratios to Average Net Assets and Supplemental Data | ||||||
Net assets, end of period ($ thousands) | 262 | 248 | 127 | 143 | 138 | 128 |
Ratio
of expenses before expense reductions (%) |
.62 ** | .63 | .65 | .64 | .61 | .62 |
Ratio
of expenses after expense reductions (%) |
.62 ** | .63 | .63 | .59 | .59 | .61 |
Ratio of net investment income (%) | 1.37 ** | 1.92 | 2.33 | 2.30 | 1.91 | 1.96 |
Portfolio turnover rate (%) | 30 * | 108 | 138 | 95 | 98 | 100 |
a | Based on average shares outstanding during the period. |
b | Total return would have been lower had certain expenses not been reduced. |
* | Not annualized |
** | Annualized |
24 | | | DWS CROCI® U.S. Fund |
DWS CROCI® U.S. Fund — Class S | ||||||
Six
Months Ended 3/31/22 |
Years Ended September 30, | |||||
(Unaudited) | 2021 | 2020 | 2019 | 2018 | 2017 | |
Selected Per Share Data | ||||||
Net asset value, beginning of period | $12.04 | $9.82 | $11.73 | $11.86 | $11.23 | $9.51 |
Income (loss) from investment operations: | ||||||
Net investment incomea | .08 | .22 | .24 | .25 | .21 | .19 |
Net realized and unrealized gain (loss) | .48 | 2.26 | (1.40) | .03 | .70 | 1.55 |
Total from investment operations | .56 | 2.48 | (1.16) | .28 | .91 | 1.74 |
Less distributions from: | ||||||
Net investment income | (.22) | (.26) | (.24) | (.28) | (.15) | (.02) |
Net realized gains | — | — | (.51) | (.13) | (.13) | — |
Total distributions | (.22) | (.26) | (.75) | (.41) | (.28) | (.02) |
Net asset value, end of period | $12.38 | $12.04 | $9.82 | $11.73 | $11.86 | $11.23 |
Total Return (%) | 4.55 * | 25.63 | (11.08) | 2.98 | 8.17 | 18.33 |
Ratios to Average Net Assets and Supplemental Data | ||||||
Net assets, end of period ($ millions) | 591 | 586 | 530 | 660 | 706 | 718 |
Ratio of expenses (%) | .66 ** | .67 | .67 | .67 | .67 | .67 |
Ratio of net investment income (%) | 1.33 ** | 1.90 | 2.28 | 2.21 | 1.83 | 1.79 |
Portfolio turnover rate (%) | 30 * | 108 | 138 | 95 | 98 | 100 |
a | Based on average shares outstanding during the period. |
* | Not annualized |
** | Annualized |
DWS CROCI® U.S. Fund | | | 25 |
DWS CROCI® U.S. Fund — Institutional Class | ||||||
Six
Months Ended 3/31/22 |
Years Ended September 30, | |||||
(Unaudited) | 2021 | 2020 | 2019 | 2018 | 2017 | |
Selected Per Share Data | ||||||
Net asset value, beginning of period | $12.03 | $9.81 | $11.72 | $11.86 | $11.23 | $9.53 |
Income (loss) from investment operations: | ||||||
Net investment incomea | .08 | .22 | .25 | .24 | .21 | .19 |
Net realized and unrealized gain (loss) | .48 | 2.26 | (1.42) | .03 | .70 | 1.54 |
Total from investment operations | .56 | 2.48 | (1.17) | .27 | .91 | 1.73 |
Less distributions from: | ||||||
Net investment income | (.22) | (.26) | (.23) | (.28) | (.15) | (.03) |
Net realized gains | — | — | (.51) | (.13) | (.13) | — |
Total distributions | (.22) | (.26) | (.74) | (.41) | (.28) | (.03) |
Net asset value, end of period | $12.37 | $12.03 | $9.81 | $11.72 | $11.86 | $11.23 |
Total Return (%) | 4.55 b* | 25.65 b | (11.11) b | 2.88 b | 8.18 | 18.20 |
Ratios to Average Net Assets and Supplemental Data | ||||||
Net assets, end of period ($ millions) | 6 | 7 | 6 | 7 | 9 | 7 |
Ratio
of expenses before expense reductions (%) |
.73 ** | .67 | .71 | .71 | .68 | .66 |
Ratio
of expenses after expense reductions (%) |
.67 ** | .67 | .67 | .69 | .68 | .66 |
Ratio of net investment income (%) | 1.31 ** | 1.91 | 2.32 | 2.14 | 1.84 | 1.87 |
Portfolio turnover rate (%) | 30 * | 108 | 138 | 95 | 98 | 100 |
a | Based on average shares outstanding during the period. |
b | Total return would have been lower had certain expenses not been reduced. |
* | Not annualized |
** | Annualized |
26 | | | DWS CROCI® U.S. Fund |
Notes to Financial Statements | (Unaudited) |
A. | Organization and Significant Accounting Policies |
DWS CROCI® U.S. Fund | | | 27 |
28 | | | DWS CROCI® U.S. Fund |
DWS CROCI® U.S. Fund | | | 29 |
30 | | | DWS CROCI® U.S. Fund |
B. | Purchases and Sales of Securities |
C. | Related Parties |
First $1.5 billion of the Fund’s average daily net assets | .425% |
Next $500 million of such net assets | .400% |
Next $1.0 billion of such net assets | .375% |
Next $1.0 billion of such net assets | .350% |
Next $1.0 billion of such net assets | .325% |
Over $5.0 billion of such net assets | .300% |
DWS CROCI® U.S. Fund | | | 31 |
Class A | 1.01% |
Class T | 1.01% |
Class C | 1.76% |
Class R | 1.26% |
Class R6 | .67% |
Class S | .76% |
Institutional Class | .67% |
Class C | $ 766 |
Class R | 439 |
Institutional Class | 1,898 |
$ 3,103 |
32 | | | DWS CROCI® U.S. Fund |
Services to Shareholders | Total
Aggregated |
Unpaid
at March 31, 2022 |
Class A | $ 27,797 | $ 9,690 |
Class T | 13 | 4 |
Class C | 910 | 328 |
Class R | 25 | 12 |
Class R6 | 61 | 13 |
Class S | 143,458 | 44,798 |
Institutional Class | 323 | 133 |
$ 172,587 | $ 54,978 |
Sub-Recordkeeping | Total
Aggregated |
Class A | $ 63,794 |
Class C | 1,397 |
Class R | 1,697 |
Class S | 112,691 |
Institutional Class | 4,659 |
$ 184,238 |
Distribution Fee | Total
Aggregated |
Unpaid
at March 31, 2022 |
Class C | $ 5,830 | $ 965 |
Class R | 1,733 | 279 |
$ 7,563 | $ 1,244 |
DWS CROCI® U.S. Fund | | | 33 |
Service Fee | Total
Aggregated |
Unpaid
at March 31, 2022 |
Annualized
Rate |
Class A | $ 127,538 | $ 40,670 | .24% |
Class T | 10 | 9 | .15% |
Class C | 1,840 | 1,083 | .24% |
Class R | 1,731 | 607 | .25% |
$ 131,119 | $ 42,369 |
34 | | | DWS CROCI® U.S. Fund |
D. | Line of Credit |
E. | Fund Share Transactions |
Six
Months Ended March 31, 2022 |
Year
Ended September 30, 2021 | |||
Shares | Dollars | Shares | Dollars | |
Shares sold | ||||
Class A | 109,810 | $ 1,365,043 | 331,528 | $ 3,733,903 |
Class C | 5,121 | 64,194 | 8,699 | 99,200 |
Class R | 4,122 | 51,232 | 8,528 | 94,162 |
Class R6 | 314 | 3,951 | 7,347 | 88,040 |
Class S | 313,458 | 3,947,051 | 521,630 | 5,932,626 |
Institutional Class | 26,286 | 330,323 | 1,220,691 | 13,846,410 |
$ 5,761,794 | $ 23,794,341 |
DWS CROCI® U.S. Fund | | | 35 |
Six
Months Ended March 31, 2022 |
Year
Ended September 30, 2021 | |||
Shares | Dollars | Shares | Dollars | |
Shares issued to shareholders in reinvestment of distributions | ||||
Class A | 109,630 | $ 1,418,612 | 193,559 | $ 2,024,624 |
Class T | 15 | 195 | 23 | 242 |
Class C | 624 | 8,007 | 2,498 | 25,926 |
Class R | 1,188 | 15,378 | 2,094 | 21,927 |
Class R6 | 356 | 4,600 | 325 | 3,390 |
Class S | 763,832 | 9,876,343 | 1,209,575 | 12,640,059 |
Institutional Class | 8,795 | 113,636 | 15,475 | 161,563 |
$ 11,436,771 | $ 14,877,731 | |||
Shares redeemed | ||||
Class A | (545,615) | $ (6,858,020) | (2,230,100) | $ (24,501,470) |
Class C | (7,558) | (95,133) | (87,699) | (999,067) |
Class R | (12,332) | (157,914) | (13,532) | (145,166) |
Class R6 | (58) | (761) | (30) | (309) |
Class S | (2,010,687) | (25,332,663) | (7,028,315) | (76,968,307) |
Institutional Class | (93,895) | (1,198,144) | (1,314,377) | (14,814,837) |
$ (33,642,635) | $ (117,429,156) | |||
Net increase (decrease) | ||||
Class A | (326,175) | $ (4,074,365) | (1,705,013) | $ (18,742,943) |
Class T | 15 | 195 | 23 | 242 |
Class C | (1,813) | (22,932) | (76,502) | (873,941) |
Class R | (7,022) | (91,304) | (2,910) | (29,077) |
Class R6 | 612 | 7,790 | 7,642 | 91,121 |
Class S | (933,397) | (11,509,269) | (5,297,110) | (58,395,622) |
Institutional Class | (58,814) | (754,185) | (78,211) | (806,864) |
$ (16,444,070) | $ (78,757,084) |
F. | Other — COVID-19 Pandemic |
36 | | | DWS CROCI® U.S. Fund |
DWS CROCI® U.S. Fund | | | 37 |
— | Actual Fund Return. This helps you estimate the actual dollar amount of ongoing expenses (but not transaction costs) paid on a $1,000 investment in the Fund using the Fund’s actual return during the period. To estimate the expenses you paid over the period, simply divide your account value by $1,000 (for example, an $8,600 account value divided by $1,000 = 8.6), then multiply the result by the number in the “Expenses Paid per $1,000” line under the share class you hold. |
— | Hypothetical 5% Fund Return. This helps you to compare your Fund’s ongoing expenses (but not transaction costs) with those of other mutual funds using the Fund’s actual expense ratio and a hypothetical rate of return of 5% per year before expenses. Examples using a 5% hypothetical fund return may be found in the shareholder reports of other mutual funds. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period. |
38 | | | DWS CROCI® U.S. Fund |
Actual Fund Return | Class A | Class T | Class C | Class R | Class R6 | Class S | Institutional
Class |
Beginning Account Value 10/1/21 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
Ending Account Value 3/31/22 | $1,043.10 | $1,044.40 | $1,039.80 | $1,041.70 | $1,045.90 | $1,045.50 | $1,045.50 |
Expenses Paid per $1,000* | $ 5.04 | $ 4.69 | $ 8.95 | $ 6.41 | $ 3.16 | $ 3.37 | $ 3.42 |
Hypothetical 5% Fund Return | Class A | Class T | Class C | Class R | Class R6 | Class S | Institutional
Class |
Beginning Account Value 10/1/21 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
Ending Account Value 3/31/22 | $1,020.00 | $1,020.34 | $1,016.16 | $1,018.65 | $1,021.84 | $1,021.64 | $1,021.59 |
Expenses Paid per $1,000* | $ 4.99 | $ 4.63 | $ 8.85 | $ 6.34 | $ 3.13 | $ 3.33 | $ 3.38 |
* | Expenses are equal to the Fund’s annualized expense ratio for each share class, multiplied by the average account value over the period, multiplied by 182 (the number of days in the most recent six-month period), then divided by 365. |
Annualized Expense Ratios | Class A | Class T | Class C | Class R | Class R6 | Class S | Institutional
Class |
DWS CROCI® U.S. Fund | .99% | .92% | 1.76% | 1.26% | .62% | .66% | .67% |
DWS CROCI® U.S. Fund | | | 39 |
40 | | | DWS CROCI® U.S. Fund |
— | During the entire process, all of the Fund’s Trustees were independent of DIMA and its affiliates (the “Independent Trustees” ). |
— | The Board met frequently during the past year to discuss fund matters and dedicated a substantial amount of time to contract review matters. Over the course of several months, the Board reviewed extensive materials received from DIMA, independent third parties and independent counsel. These materials included an analysis of the Fund’s performance, fees and expenses, and profitability from a fee consultant retained by the Fund’s Independent Trustees (the “Fee Consultant” ). |
— | The Board also received extensive information throughout the year regarding performance of the Fund. |
— | The Independent Trustees regularly met privately with counsel to discuss contract review and other matters. In addition, the Independent Trustees were advised by the Fee Consultant in the course of their review of the Fund’s contractual arrangements and considered a comprehensive report prepared by the Fee Consultant in connection with their deliberations. |
— | In connection with reviewing the Agreement, the Board also reviewed the terms of the Fund’s Rule 12b-1 plan, distribution agreement, administrative services agreement, transfer agency agreement and other material service agreements. |
DWS CROCI® U.S. Fund | | | 41 |
42 | | | DWS CROCI® U.S. Fund |
DWS CROCI® U.S. Fund | | | 43 |
44 | | | DWS CROCI® U.S. Fund |
DWS CROCI® U.S. Fund | | | 45 |
For More Information | The automated telephone system allows you to access personalized account information and obtain information on other DWS funds using either your voice or your telephone keypad. Certain account types within Classes A, T, C and S also have the ability to purchase, exchange or redeem shares using this system. |
For
more information, contact your financial representative. You may also access our automated telephone system or speak with a Shareholder Service representative by calling: (800) 728-3337 | |
Web Site | dws.com View your account transactions and balances, trade shares, monitor your asset allocation, subscribe to fund and account updates by e-mail, and change your address, 24 hours a day. |
Obtain prospectuses and applications, news about DWS funds, insight from DWS economists and investment specialists and access to DWS fund account information. | |
Written Correspondence | DWS
PO Box 219151 Kansas City, MO 64121-9151 |
Proxy Voting | The Fund’s policies and procedures for voting proxies for portfolio securities and information about how the Fund voted proxies related to its portfolio securities during the most recent 12-month period ended June 30 are available on our Web site — dws.com/en-us/resources/proxy-voting — or on the SEC’s Web site — sec.gov. To obtain a written copy of the Fund’s policies and procedures without charge, upon request, call us toll free at (800) 728-3337. |
Portfolio Holdings | Following the Fund’s fiscal first and third quarter-end, a complete portfolio holdings listing is posted on dws.com, and is available free of charge by contacting your financial intermediary, or if you are a direct investor, by calling (800) 728-3337. In addition, the portfolio holdings listing is filed with SEC on the Fund’s Form N-PORT and will be available on the SEC’s Web site at sec.gov. Additional portfolio holdings for the Fund are also posted on dws.com from time to time. Please see the Fund’s current prospectus for more information. |
Principal Underwriter | If
you have questions, comments or complaints, contact:DWS Distributors, Inc. 222 South Riverside Plaza Chicago, IL 60606-5808 (800) 621-1148 |
46 | | | DWS CROCI® U.S. Fund |
Investment Management | DWS Investment Management Americas, Inc. (“DIMA” or the “Advisor” ), which is part of the DWS Group GmbH & Co. KGaA (“DWS Group” ), is the investment advisor for the Fund. DIMA and its predecessors have more than 90 years of experience managing mutual funds and DIMA provides a full range of investment advisory services to both institutional and retail clients. DIMA is an indirect, wholly owned subsidiary of DWS Group. |
DWS Group is a global organization that offers a wide range of investing expertise and resources, including hundreds of portfolio managers and analysts and an office network that reaches the world’s major investment centers. This well-resourced global investment platform brings together a wide variety of experience and investment insight across industries, regions, asset classes and investing styles. |
Class A | Class T | Class C | Class S | Institutional Class | |
Nasdaq Symbol | DCUAX | DCUUX | DCUCX | DCUSX | DCUIX |
CUSIP Number | 25157M 588 | 25157M 448 | 25157M 570 | 25157M 547 | 25157M 554 |
Fund Number | 1020 | 1720 | 1320 | 2020 | 1420 |
For shareholders of Class R and Class R6 | ||
Automated Information Line | DWS/Ascensus Plan Access (800) 728-3337 | |
24-hour access to your retirement plan account. | ||
Web Site | dws.com | |
Obtain
prospectuses and applications, news about DWS funds, insight from DWS economists and investment specialists and access to DWS fund account information. | ||
Log in/register to manage retirement account assets at https://www.mykplan.com/participantsecure_net/login.aspx. | ||
For More Information | (800) 728-3337 | |
To speak with a service representative. | ||
Written Correspondence | DWS
Service Company222 South Riverside Plaza Chicago, IL 60606-5806 |
Class R | Class R6 | |
Nasdaq Symbol | DCUTX | DCURX |
CUSIP Number | 25157M 513 | 25157M 562 |
Fund Number | 1520 | 1620 |
DWS CROCI® U.S. Fund | | | 47 |
FACTS | What Does DWS Do With Your Personal Information? |
Why? | Financial companies choose how they share your personal information. Federal law gives consumers the right to limit some but not all sharing. Federal law also requires us to tell you how we collect, share and protect your personal information. Please read this notice carefully to understand what we do. |
What? | The
types of personal information we collect and share can include: — Social Security number — Account balances — Purchase and transaction history — Bank account information — Contact information such as mailing address, e-mail address and telephone number |
How? | All financial companies need to share customers’ personal information to run their everyday business. In the section below, we list the reasons financial companies can share their customers’ personal information, the reasons DWS chooses to share and whether you can limit this sharing. |
Reasons we can share your personal information | Does DWS share? | Can
you limit this sharing? |
For our everyday business purposes —such as to process your transactions, maintain your account(s), respond to court orders or legal investigations | Yes | No |
For our marketing purposes — to offer our products and services to you | Yes | No |
For joint marketing with other financial companies | No | We do not share |
For our affiliates’ everyday business purposes — information about your transactions and experiences | No | We do not share |
For our affiliates’ everyday business purposes — information about your creditworthiness | No | We do not share |
For non-affiliates to market to you | No | We do not share |
Questions? | Call (800) 728-3337 or e-mail us at service@dws.com |
48 | | | DWS CROCI® U.S. Fund |
Who we are | |
Who is providing this notice? | DWS
Distributors, Inc; DWS Investment Management Americas, Inc.; DWS Trust Company; the DWS Funds |
What we do | |
How does DWS protect my personal information? | To protect your personal information from unauthorized access and use, we use security measures that comply with federal law. These measures include computer safeguards, secured files, and secured buildings. |
How does DWS collect my personal information? | We
collect your personal information, for example, when you: — open an account — give us your contact information — provide bank account information for ACH or wire transactions — tell us where to send money — seek advice about your investments |
Why can’t I limit all sharing? | Federal
law gives you the right to limit only — sharing for affiliates’ everyday business purposes — information about your creditworthiness — affiliates from using your information to market to you — sharing for non-affiliates to market to you State laws and individual companies may give you additional rights to limit sharing. |
Definitions | |
Affiliates | Companies
related by common ownership or control. They can be financial or non-financial companies. Our affiliates include financial companies with the DWS or Deutsche Bank (“DB” ) name, such as DB AG Frankfurt. |
Non-affiliates | Companies
not related by common ownership or control. They can be financial and non-financial companies. Non-affiliates we share with include account service providers, service quality monitoring services, mailing service providers and verification services to help in the fight against money laundering and fraud. |
Joint marketing | A
formal agreement between non-affiliated financial companies that together market financial products or services to you. DWS does not jointly market. |
DWS CROCI® U.S. Fund | | | 49 |
(b) Not applicable | ||
ITEM 2. | CODE OF ETHICS | |
Not applicable. | ||
ITEM 3. | AUDIT COMMITTEE FINANCIAL EXPERT | |
Not applicable | ||
ITEM 4. | PRINCIPAL ACCOUNTANT FEES AND SERVICES | |
Not applicable | ||
ITEM 5. | AUDIT COMMITTEE OF LISTED REGISTRANTS | |
Not applicable | ||
ITEM 6. | SCHEDULE OF INVESTMENTS | |
Not applicable | ||
ITEM 7. | DISCLOSURE OF PROXY VOTING POLICIES AND PROCEDURES FOR CLOSED-END MANAGEMENT INVESTMENT COMPANIES | |
Not applicable | ||
ITEM 8. | PORTFOLIO MANAGERS OF CLOSED-END MANAGEMENT INVESTMENT COMPANIES | |
Not applicable | ||
ITEM 9. | PURCHASES OF EQUITY SECURITIES BY CLOSED-END MANAGEMENT INVESTMENT COMPANY AND AFFILIATED PURCHASERS | |
Not applicable | ||
ITEM 10. | SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS | |
There were no material changes to the procedures by which shareholders may recommend nominees to the Fund’s Board. The primary function of the Nominating and Governance Committee is to identify and recommend individuals for membership on the Board and oversee the administration of the Board Governance Guidelines. Shareholders may recommend candidates for Board positions by forwarding their correspondence by U.S. mail or courier service to Keith R. Fox, DWS Funds Board Chair, c/o Thomas R. Hiller, Ropes & Gray LLP, Prudential Tower, 800 Boylston Street, Boston, MA 02199-3600. | ||
ITEM 11. | CONTROLS AND PROCEDURES | |
(a) | The Chief Executive and Financial Officers concluded that the Registrant’s Disclosure Controls and Procedures are effective based on the evaluation of the Disclosure Controls and Procedures as of a date within 90 days of the filing date of this report. | |
(b) | There have been no changes in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal controls over financial reporting. | |
ITEM 12. | Disclosure of Securities Lending Activities for Closed-End Management Investment Companies. | |
Not applicable | ||
ITEM 13. | EXHIBITS | |
(a)(1) | Not applicable | |
(a)(2) | Certification pursuant to Rule 30a-2(a) under the Investment Company Act of 1940 (17 CFR 270.30a-2(a)) is filed and attached hereto as Exhibit 99.CERT. | |
(b) | Certification pursuant to Rule 30a-2(b) under the Investment Company Act of 1940 (17 CFR 270.30a-2(b)) is furnished and attached hereto as Exhibit 99.906CERT. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Registrant: | DWS CROCI® U.S. Fund, a series of Deutsche DWS Investment Trust |
By: |
/s/Hepsen Uzcan Hepsen Uzcan President |
Date: | 5/27/2022 |
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
By: |
/s/Hepsen Uzcan Hepsen Uzcan President |
Date: | 5/27/2022 |
By: |
/s/Diane Kenneally Diane Kenneally Chief Financial Officer and Treasurer |
Date: | 5/27/2022 |
President
Form N-CSRS Certification under Sarbanes Oxley Act
I, Hepsen Uzcan, certify that:
1) | I have reviewed this report, filed on behalf of DWS CROCI® U.S. Fund, a series of Deutsche DWS Investment Trust, on Form N-CSRS; | ||
2) | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | ||
3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report; | ||
4) | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have: | ||
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | ||
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | ||
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and | ||
d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and | ||
5) | The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): | ||
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and | ||
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting | ||
5/27/2022 | /s/Hepsen Uzcan |
Hepsen Uzcan | |
President |
Chief Financial Officer and Treasurer
Form N-CSRS Certification under Sarbanes Oxley Act
I, Diane Kenneally, certify that:
1) | I have reviewed this report, filed on behalf of DWS CROCI® U.S. Fund, a series of Deutsche DWS Investment Trust, on Form N-CSRS; | ||
2) | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | ||
3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report; | ||
4) | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have: | ||
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | ||
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | ||
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and | ||
d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and | ||
5) | The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): | ||
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and | ||
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting | ||
5/27/2022 | /s/Diane Kenneally |
Diane Kenneally | |
Chief Financial Officer and Treasurer |
President
Section 906 Certification under Sarbanes Oxley Act
I, Hepsen Uzcan, certify that:
1. | I have reviewed this report, filed on behalf of DWS CROCI® U.S. Fund, a series of Deutsche DWS Investment Trust, on Form N-CSRS; |
2. | Based on my knowledge and pursuant to 18 U.S.C. § 1350, the periodic report on Form N-CSRS (the “Report”) fully complies with the requirements of § 13 (a) or § 15 (d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
5/27/2022 | /s/Hepsen Uzcan |
Hepsen Uzcan | |
President |
Chief Financial Officer and Treasurer
Section 906 Certification under Sarbanes Oxley Act
I, Diane Kenneally, certify that:
1. | I have reviewed this report, filed on behalf of DWS CROCI® U.S. Fund, a series of Deutsche DWS Investment Trust, on Form N-CSRS; |
2. | Based on my knowledge and pursuant to 18 U.S.C. § 1350, the periodic report on Form N-CSRS (the “Report”) fully complies with the requirements of § 13 (a) or § 15 (d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
5/27/2022 | /s/Diane Kenneally |
Diane Kenneally | |
Chief Financial Officer and Treasurer |